Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial

Although azacitidine is the first‐line drug for higher‐risk myelodysplastic syndrome (MDS) patients, its efficacy for lower‐risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5‐day regimen of azacitidine (AZA‐5) for lower‐risk MDS. The...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Sci
मुख्य लेखकों: Morita, Yasuyoshi, Maeda, Yasuhiro, Yamaguchi, Terufumi, Urase, Fumiaki, Kawata, Shuhei, Hanamoto, Hitoshi, Tsubaki, Kazuo, Ishikawa, Jun, Shibayama, Hirohiko, Matsumura, Itaru, Matsuda, Mitsuhiro
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2018
विषय:
Original Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172056/
https://ncbi.nlm.nih.gov/pubmed/30007103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13739
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन